Walgreens completes purchase of McKesson Specialty Pharmacy
DEERFIELD, Ill. Walgreens on Monday announced the completion of its acquisition of McKesson Corporation’s specialty pharmacy, which includes the McKesson Specialty Pharmacy in Pittsburgh and IVPCARE, a specialty pharmacy focused on reproductive health based in Frisco, Texas, with operations in Torrance, Calif., Wilmington, Mass. and St. Louis.
“This acquisition further expands our national capabilities and access to managed care payors,” stated Michael Nameth, executive vice president of Walgreens Health Services.
Walgreens Specialty Pharmacy, a wholly-owned subsidiary of Walgreen Co. operated by its managed care division, Walgreens Health Services, is a national provider of injectable and biopharmaceutical medications dedicated to serving the needs of patients living with complex, chronic health and medical conditions. Walgreens Specialty Pharmacy provides personalized care and services through dedicated fulfillment centers across the country and through more than 6,500 electronically linked Walgreens pharmacies, including locations in academic medical centers, community hospitals and physician office buildings.
FDA grants tentative approval for generic version of Zyprexa
ROCKVILLE, Md. The Food and Drug Administration has granted tentative approval to Roxane Labs’ generic version of Eli Lilly and Co.’s antipsychotic drug, Zyprexa, FDA records show.
The FDA passed tentative approval for the generic version of the drug in the 5 mg strength Nov. 20.
Several other drug makers, such as Teva, Mylan, Sandoz and Barr Labs, also are developing generic versions of Zyprexa.
Approval application withdrawn by Eli Lilly
INDIANAPOLIS Eli Lilly and Co. has withdrawn an application seeking approval from the Food and Drug Administration to market its antidepressant Cymbalta for treating chronic pain, the Indianapolis-based drug maker said Friday.
Citing a need for more data, Lilly said it plans to resubmit the application in the first half of next year for the added use of the drug.
“This was a difficult decision, but we believe the updated data package will give the FDA a broader basis for reviewing our application,” vice president of Lilly Research Laboratories John Hayes said in a statement.
Cymbalta (duloxetine hydrochloride) is already approved for treating depression, anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia.